Circulating cfDNA and HPV as Prognostic Biomarkers for First-Line Recurrent Metastatic Cervical Cancer
Starting soon
Conditions studied: Cervical Cancer, Recurrent Cervical Cancer, Metastatic Cervical Cancer
In brief
Primary Objective of this study: To investigate the correlation between longitudinal quantitative dynamics of circulating tumor DNA (ctDNA) and HPV-derived cell-free DNA (HPV cfDNA) in peripheral blood and clinical prognosis among patients with recurrent and metastatic cervical cancer who achieved complete response following standard first-line systemic therapy.
Key facts
- Study ID
- NCT07673211
- Run by
- Zhejiang Cancer Hospital
- People needed
- 60
- Starts
- 2026-06-01
- Expected to finish
- 2029-12-01
- Last updated by the study team
- 2026-06-29
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Histopathologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma;
- Patients with first recurrent or metastatic cervical cancer (including primary stage IVB disease);
- Received standard first-line therapy (TP/TC regimen plus immunotherapy ± bevacizumab);
- Achieved complete response (CR) following standard first-line treatment;
- Archived pathological biopsy specimens of recurrent/metastatic lesions prior to treatment available in our hospital;
- Participated in clinical trials of pharmaceutical therapy for first-line recurrent/metastatic cervical cancer conducted at our institution;
- Voluntarily participates in this study and provides written informed consent;
- Agrees to serial peripheral blood collection at scheduled time points;
- Willing to complete scheduled follow-up visits;
- Aged ≥ 18 years old.
You may not qualify if…
- History of other malignant tumors within the past 2 years;
- Pregnant or breastfeeding women;
- Severe concomitant diseases, including: cardiovascular diseases (e.g., uncontrolled heart failure, unstable angina, etc.); pulmonary diseases (e.g., severe chronic obstructive pulmonary disease, interstitial pneumonia and other conditions impairing respiratory function); hepatic and renal dysfunction (e.g., decompensated liver cirrhosis, severe renal failure requiring dialysis, etc.);
- Refusal to sign informed consent;
- Refusal to undergo serial blood collection.
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.